![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-first-quarter-of-2024-302145383.html
https://www.prnewswire.com/news-releases/astellas-and-poseida-therapeutics-enter-into-research-collaboration-and-license-agreement-to-develop-novel-allogeneic-cell-therapies-in-oncology-302133127.html
https://www.prnewswire.com/news-releases/poseida-therapeutics-presents-new-phase-1-data-at-aacr-2024-supporting-potential-of-p-bcma-allo1-allogeneic-car-t-therapy-to-benefit-broad-range-of-patients-with-multiple-myeloma-302110563.html
https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-2nd-annual-cell-therapy-virtual-conference-302092083.html
https://www.fiercebiotech.com/biotech/after-fda-car-t-concerns-poseida-shares-early-data-roche-partnered-nonviral-approach
https://endpts.com/poseida-promotes-cell-therapy-president-to-ceo-after-ipo-neumora-appoints-rd-chief/
https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-p-cd19cd20-allo1-an-allogeneic-dual-car-t-cell-therapy-for-b-cell-malignancies-301868955.html
https://www.prnewswire.com/news-releases/poseida-therapeutics-presents-encouraging-preclinical-data-across-its-gene-therapy-programs-at-the-american-society-for-gene-and-cell-therapy-2023-annual-meeting-301827986.html
https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-first-quarter-of-2023-301820079.html
https://www.contractpharma.com/contents/view_breaking-news/2023-04-11/poseida-therapeutics-names-kristin-yarema-presiden/?widget=listSection